China plans to tighten medical device regs; Cardium notches patent win over Boston Sci;

 @FierceMedDev: FDA faults St. Jude's manufacturing for Durata ICD leads. St. Jude disclosed the report but kept "Durata" out. More | Follow @FierceMedDev

 @MarkHFierce: Zimmer will train regulators in China in an unusual deal. Release | Follow @MarkHFierce

 @DamianFierce: Novartis' Alcon is buying the ophthalmic surgery unit of German company SensoMotoric. Story | Follow @DamianFierce

> China's State Food and Drug Administration begins new regulations on Jan. 1, designed, in part, to worsen the punishment for device companies that commit specific violations. Story

> Medtronic ($MDT) reported a quarterly drop in profits yesterday, but stabilizing revenues in its spinal and heart devices were good enough for investors, and the company's stocked jumped about 3% as of Wednesday morning. More

> St. Jude Medical's ($STJ) legal woes over its recalled Riata leads seem far from over, as more and more law firms join the litigious horde on its tail. Release

> Cardium Therapeutics ($CXM) says it has won a legal battle with Boston Scientific ($BSX) over patents for cardiovascular gene therapy. Item

> Sano Intelligence is developing a transdermal patch that continually monitors an individual's blood-makeup and transmits the data wirelessly. Item

> Medical device maker AngioDynamics has hired a new chief financial officer to replace D. Joseph Gersuk, who is retiring. Story

Biotech News

 @FierceBiotech: Predicting your end: Biomarkers for mortality. News | Follow @FierceBiotech

 @JohnCFierce: Feds zero in on drug experts as insider case exposes investigator's role (more to come, I suspect). Story | Follow @JohnCFierce

 @RyanMFierce: With ex-BMSer Jeremy Levin at the helm, Teva wants to do buyouts that are smaller than the deals that made Teva big. More | Follow @RyanMFierce

> Xoma hunts for marketing partner as blood pressure med clears PhIII. Article

> Pfizer, Bristol-Myers win landmark European approval for Eliquis. Story

Pharma News

@FiercePharma: Novartis nabs FDA approval for 1st flu vaccine made without eggs. Produced at plant that got $500M in gov't aid. More (sub. req.) | Follow @FiercePharma

> New Teva CEO, new small-is-beautiful M&A strategy. Report

> Novartis fast production, cell-culture flu vaccine OK'd by FDA. Article

> Armed with EU stroke approval, Pfizer, BMS talk up Eliquis' edge over rivals. Story

> PwC sees golden era for pharmas that dump the junk, innovate. News

Drug Delivery News

> Fujifilm joins microneedle R&D boom. Report

> Reinforced gels deliver drugs and cells. Article

> Pfizer hits ups, downs with controlled-release Lyrica. News

> Nanoparticles deliver antigen to trick the immune system in MS. Story

Biomarkers News

> Predicting your end: Biomarkers for mortality. Article

> Kidney problems tag development delays? Story

> Saliva markers diagnose gum disease. News

> DoD's $1.15M grant may lead to blood test to catch heavy drinkers. Item

Vaccine News

> J&J hits development roadblock with Crucell candidates. Article

> FDA panel concerned about safety of Dynavax's hep B vaccine. News

> Novartis nabs EU committee backing for meningitis B vaccine. Story

> GSK's Synflorix gleans positive results in infants. Report

> FDA approves Novartis flu vaccine. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.